Samuel Joseph* and Lauren Edge
Introduction: Minimally-invasive transforaminal lumbar interbody fusion offers a conservative surgical option designed to reduce complications. A novel allograft growth factor including multiple factors associated with bone remodeling is utilized and independently assessed for efficacy in supporting fusion.
Case presentation: To evaluate post-surgical follow-up radiology for fusion status of MI-TLIF levels implementing novel allograft growth factor to support bony remodeling
Methods: A fellowship trained orthopedic surgeon collected 102 consecutive studies and was granted a waiver by an Institutional Review Board for retrospective assessment of post-surgical radiology to follow state of fusion.
Results: At three months, 72 of 104 (69.2%) levels assessed were deemed to be fused, at six months 87 of 116 (75.0%) levels assessed were deemed to be fused, at twelve months 107 of 113 (94.7%) levels assessed were deemed to be fused, at eighteen months 107 of 109 (98.2%) levels assessed were deemed to be fused and ultimately at twenty-one months all 108 of 108 (100%) levels reviewed were deemed to be fused.
Conclusion: Novel allograft growth factor demonstrates efficacy with regards to supporting bony fusion with regards to MI-TLIF procedures observed.
HTML PDFShare this article
Journal of Spine received 2022 citations as per Google Scholar report
